Browse STAT6

Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Note=Translocated into the nucleus in response to phosphorylation.
Domain PF00017 SH2 domain
PF14596 STAT6 C-terminal
PF01017 STAT protein
PF02864 STAT protein
PF02865 STAT protein
Function

Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0000302 response to reactive oxygen species
GO:0001819 positive regulation of cytokine production
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002295 T-helper cell lineage commitment
GO:0002296 T-helper 1 cell lineage commitment
GO:0002312 B cell activation involved in immune response
GO:0002360 T cell lineage commitment
GO:0002363 alpha-beta T cell lineage commitment
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002828 regulation of type 2 immune response
GO:0002829 negative regulation of type 2 immune response
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006310 DNA recombination
GO:0006979 response to oxidative stress
GO:0007159 leukocyte cell-cell adhesion
GO:0010035 response to inorganic substance
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0019724 B cell mediated immunity
GO:0022612 gland morphogenesis
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030879 mammary gland development
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032606 type I interferon production
GO:0033598 mammary gland epithelial cell proliferation
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035771 interleukin-4-mediated signaling pathway
GO:0042088 T-helper 1 type immune response
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042542 response to hydrogen peroxide
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043368 positive T cell selection
GO:0043369 CD4-positive or CD8-positive, alpha-beta T cell lineage commitment
GO:0043373 CD4-positive, alpha-beta T cell lineage commitment
GO:0045058 T cell selection
GO:0045063 T-helper 1 cell differentiation
GO:0045165 cell fate commitment
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045830 positive regulation of isotype switching
GO:0045911 positive regulation of DNA recombination
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0048289 isotype switching to IgE isotypes
GO:0048293 regulation of isotype switching to IgE isotypes
GO:0048295 positive regulation of isotype switching to IgE isotypes
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050777 negative regulation of immune response
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0060443 mammary gland morphogenesis
GO:0061180 mammary gland epithelium development
GO:0070301 cellular response to hydrogen peroxide
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070670 response to interleukin-4
GO:0071353 cellular response to interleukin-4
GO:0071593 lymphocyte aggregation
GO:1902170 cellular response to reactive nitrogen species
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0044454 nuclear chromosome part
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-186763: Downstream signal transduction
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-3249367: STAT6-mediated induction of chemokines
R-HSA-1834941: STING mediated induction of host immune responses
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STAT6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between STAT6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26928313Hepatocellular CarcinomaPromote immunity (T cell function)TLR4-mediated BCL6 upregulation was crucial for PD-1(hi) B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation. Importantly, upon encountering PD-L1(+) cells or undergoing PD-1 triggering, PD-1(hi) B cells acquired regulatory functions that suppressed tumor-specific T-cell immunity and promoted cancer growth via IL10 signals.
29634251lung carcinomaPromote immunityThe reversion of TAMs is proved to be mainly controlled by suppressing STAT6 and activating NF-κB phosphorylation.
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STAT6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STAT6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1340.642
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1180.964
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1370.939
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0880.785
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0460.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2550.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2690.552
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2660.898
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2630.91
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4790.823
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8150.798
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2340.003
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STAT6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STAT6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STAT6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STAT6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STAT6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STAT6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STAT6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTAT6
Namesignal transducer and activator of transcription 6, interleukin-4 induced
Aliases D12S1644; IL-4-STAT; IL-4-STATB; STAT6C; STAT, interleukin4-induced; transcription factor IL-4 STAT; IL-4 St ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STAT6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.